44
Participants
Start Date
June 20, 2017
Primary Completion Date
June 23, 2023
Study Completion Date
June 23, 2023
Questionnaire Administration
Ancillary studies
Trametinib
Given PO
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Montefiore Medical Center-Einstein Campus, The Bronx
Montefiore Medical Center-Weiler Hospital, The Bronx
Montefiore Medical Center - Moses Campus, The Bronx
Roswell Park Cancer Institute, Buffalo
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Fox Chase Cancer Center, Philadelphia
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Duke University Medical Center, Durham
Vanderbilt Breast Center at One Hundred Oaks, Nashville
Vanderbilt University/Ingram Cancer Center, Nashville
Ohio State University Comprehensive Cancer Center, Columbus
Cleveland Clinic Foundation, Cleveland
University of Michigan Comprehensive Cancer Center, Ann Arbor
Mayo Clinic in Rochester, Rochester
Northwestern University, Chicago
Washington University School of Medicine, St Louis
Siteman Cancer Center at West County Hospital, Creve Coeur
University of Kansas Clinical Research Center, Fairway
Nebraska Medicine-Village Pointe, Omaha
Nebraska Medicine-Bellevue, Bellevue
University of Nebraska Medical Center, Omaha
M D Anderson Cancer Center, Houston
UCHealth University of Colorado Hospital, Aurora
Huntsman Cancer Institute/University of Utah, Salt Lake City
Mayo Clinic Hospital in Arizona, Phoenix
Mayo Clinic in Arizona, Scottsdale
Stanford Cancer Institute Palo Alto, Palo Alto
Smilow Cancer Center/Yale-New Haven Hospital, New Haven
Yale University, New Haven
Mayo Clinic in Florida, Jacksonville
Massachusetts General Hospital Cancer Center, Boston
Brigham and Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
National Cancer Institute (NCI)
NIH